Eine Mann füllt mit einer Pipette eine rote Flüssigkeit in ein kleines Glas

Aktuelle Publikationen


Sie befinden sich hier:

Aktuelle Publikationen aus Klinik und Forschung (Auswahl)

der Medizinischen Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie (CBF)


Mertens D, Krönke J.: Triggering T-cell activity in CLL.  Blood. 2021 

Wulf GG, Altmann B, Ziepert M, (...) Pezzutto A, (...) Schmitz N, Trümper L; ACT-2 study investigators.: Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.  Leukemia. 2021


Kroschinsky F, Middeke JM, Janz M (...) Burkard U, Berk A, Schmitz N.: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Invest New Drugs. 2020

Teck AT, Urban S, Quass P, (...) Letsch A, Busse A, Walz JS, Keilholz U, Ochsenreither S.: Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo. Cancer Immunol Immunother. 2020

Biederstädt, A., Hassan, Z., Schneeweis, C., Schick, M., (...) Wirth, M., (...) Reichert, M., Schneider, G., Keller, U.: SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Gut. 2020

Jesinghaus, M., Steiger, K., Stögbauer, F. (...) Wirth, M. (...), Klinghammer, K. (...) Combs, S.E., Weichert, W., Boxberg, M.: Pre-operative cellular dissociation grading in biopsies is highly predictive of post-operative tumour stage and patient outcome in head and neck squamous cell carcinoma. Br J Cancer. 2020

Poeschel V, Held, G, Ziepert M, (...) Keller U, (...) Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance.:  Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.  Lancet. 2020

Rambaldi A, Iurlo A, Vannucchi AM, (...) Pezzutto A, (...), Bettica P, Manzoni S, Di Tollo S.: Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study. Leukemia. 2020

Lamping M, Benary M, Leyvraz S, (...) Klinghammer K, Ochsenreither S, (...) Yaspo ML, Keilholz U, Rieke DT.: Support of a molecular tumour board by an evidence-based decision management system for precision oncology.  Eur J Cancer. 2020

Mylonas E, Yoshida K, Frick M, (...) Obenaus M, (...) Rose-Zerilli MJJ, Ogawa S, Damm F.:  Single-cell analysis based dissection of clonality in myelofibrosis.  Nat Commun. 2020

Ruhnke M, Cornely OA, Schmidt-Hieber M, (...), von Lilienfeld-Toal M, Weissinger F, Schwartz S.: Treatment of invasive fungal diseases in cancer patients - Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Mycoses. 2020

Topp MS, Duell J, Zugmaier G, (...) Krönke J, (...) Minella AC, Munzert G, Einsele H.: Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.  J Clin Oncol. 2020

Wagner AH, Walsh B, Mayfield G, (...) Rieke DT, (...) Griffith OL, Margolin AA; Variant Interpretation for Cancer Consortium.: A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer.  Nat Genet. 2020

Rohrmoser A, Pichler T, Letsch A (...) Keilholz U (...) Heinemann V, Westphalen CB, Goerling U.: Cancer patients´ expectations when undergoing extensive molecular diagnostics-A qualitative study: Psychooncology. 2020

Thomssen C, Lüftner D (...) Schwoerer M, Steinfeld-Birg D, Ziegler-Löhr K: International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts. Breast Care (Basel). 2020

Schneeweiss A, Hartkopf AD, Müller V (...) Lüftner D, Schütz F: Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies. Geburtshilfe Frauenheilkd. 2020

Lüftner D, (...) Schneeweiss A, Hartkopf AD, Müller V: Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. Geburtshilfe Frauenheilkd. 2020

Herhaus P, Lipkova J, Lammer F, (...) Habringer S, (...) Weber WA, Menze B, Keller U.: CXCR4-targeted positron emission tomography imaging of central nervous system B-cell lymphoma. J Nucl Med. 2020

Bröckelmann PJ, Goergen H, Keller U, (...) Mathas S, (...) Kobe C, Borchmann P, Engert A.: Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial. JAMA Oncol. 2020

Toews K, Grunewald L, Schwiebert S, (...) Ochsenreither S, Eggert A, Künkele A.: Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells. Mol Carcinog. 2020

Bamopoulos SA, Batcha AMN, Jurinovic V (...), Spiekermann K, Metzeler KH, Herold T: Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia. Leukemia. 2020

Opatz S, Bamopoulos SA, Metzeler KH, (...) Spiekermann K, Bohlander SK, Greif PA: The clinical mutatome of core binding factor leukemia. Leukemia. 2020

Raab MS, Engelhardt M, Blank A (...) Blau IW (...) Jarutat T, Peschel C, Chatterjee M: MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. Haematol. 2020

Goldschmidt H, Mai EK, Dürig J (...) Blau IW ( ...) Raab MS, Hänel M, Salwender HJ: German-speaking Myeloma Multicenter Group (GMMG): Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia. 2020

Kiefer T, Krahl D, Kohlmann T, Nogai A (...) Völler H, Buhlert H, Daeschlein G: Does rehabilitation pose a risk to patients suffering from haemato-oncological diseases?. Eur J Cancer Care. 2020

Wulf GG, Altmann B, Ziepert M, (...) Pezzutto A, (...) Schmitz N, Trümper L: ACT-2 study investigators: Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.  Leukemia. 2020

Toboso-Navasa A, Gunawan A, Morlino G, (...) Janz M, (...) Brink R, Eilers M, Calado DP: Restriction of memory B cell differentiation at the germinal center B cell positive selection stage. J Exp Med. 2020

Messerschmidt C, Obermayer B, Klinghammer K, Ochsenreither S, (...) Keilholz U, Beule D, Rieke DT: Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC. Int J Cancer. 2020

Kiweler N, Wünsch D, Wirth M, (...) Brenner W, Butter F, Krämer OH: Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes J Cancer Res Clin Oncol. 2020

Hess G, Wagner K, Keller U, (...); Klapper W, Theobald M, Dreyling M: Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma.  HemaSphere. 2020

Oing C, Hentrich M, Lorch A, (...) Ochsenreither S, (...) Pereira RR, Bokemeyer C, Seidel C. Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series. J Cancer Res Clin Oncol. 2020

Rogasch JMM, Furth C, Chibolela C, (...) Ochsenreither S, (...) von Laffert M, Amthauer H: Frost N. Validation of Independent Prognostic Value of Asphericity of 18F-Fluorodeoxyglucose Uptake in Non-Small-Cell Lung Cancer Patients Undergoing Treatment With Curative Intent. Clin Lung Cancer. 2020

Delgado-Benito V, Berruezo-Llacuna M, Altwasser R, (...) Janz M, Akalin A, Di Virgilio M: PDGFA-associated protein 1 protects mature B lymphocytes from stress-induced cell death and promotes antibody gene diversification. J Exp Med. 2020

Frost N, Zhamurashvili T, von Laffert M, (...) Ochsenreither S, (...) Suttorp N, Grohé C, Witzenrath M: Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis. Clin Lung Cancer. 2020

Goldschmidt H, Baertsch MA, Schlenzka J, (...) Nogai A, (...) Besemer B, Weisel K; German Myeloma Multicenter Group (GMMG): Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia. 2020

Tinhofer I, Braunholz D, Klinghammer K: Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies. Cancers Head Neck. 2020

Pouyiourou M, Meyer A, Stroux A, (...) Keller U, (...) Herold M, Scholz CW; East German Study Group for Hematology and Oncology (OSHO): First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis. Ann Hematol. 2020

Hess G, Wagner K, Keller U, (...) Klapper W, Theobald M, Dreyling M.: Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma. Hemasphere. 2020

Lüftner D, Lyman GH, Gonçalves J, Pivot X, Seo M.: Biologic Drug Quality Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3. Target Oncol. 2020

Meyer T, Jahn N, Lindner S, (...) Bullinger L, Döhner K, Krönke J.: Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1). Leukemia. 2020

Gronbach L, Wolff C, Klinghammer K, (...) Tinhofer I, Keilholz U, Zoschke C.: A multilayered epithelial mucosa model of head neck squamous cell carcinoma for analysis of tumor-microenvironment interactions and drug development. Biomaterials. 2020

Kapp-Schwoerer S, Weber D, Corbacioglu A, (...) Krönke J, (...) Ganser A, Döhner H, Döhner K.: Impact of gemtuzumab ozogamicin on MRD and relapse risk in NPM1 mutated AML patients: results from the AMLSG 09-09 Trial. Blood. 2020

Kim D, Elgeti T, Penzkofer T, (...) Schwartz S, Hamm B, Nagel SN: Enhancing the differentiation of pulmonary lymphoma and fungal pneumonia in hematological patients using texture analysis in 3-T MRI. Eur Radiol. 2020

Mrotzek SM, Lena A, Hadzibegovic S, (...) Keller U, (...) Rassaf T, Anker MS, Totzeck M: Assessment of coronary artery disease during hospitalization for cancer treatment. Clin Res Cardiol. 2020

Kubasch AS, Schulze F, Giagounidis A, (...) Krönke J, (...) Adès L, Oelschlägel U, Platzbecker U: Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia. 2020

Pichler T, Rohrmoser A, Letsch A, (...) Keilholz U, (...) Lamping M, (...) Riedmann K, Herschbach P, Goerling U: Information, communication, and cancer patients' trust in the physician: what challenges do we have to face in an era of precision cancer medicine? Support Care Cancer. 2020

Hermann M, Kühne F, Rohrmoser A, (...) Letsch A: Perspectives of patients with multiple myeloma on accepting their prognosis-A qualitative interview study. Psychooncology. 2020

Dantes Z, Yen HY, Pfarr N, (...) Wirth M, (...) Schmid RM, Schneider G, Reichert M: Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. JCI Insight. 2020

Scholz F, Grau M, Menzel L, (...) Janz M, Lenz G, Rehm A, Höpken UE: The transcription factor C/EBPβ orchestrates dendritic cell maturation and functionality under homeostatic and malignant conditions. Proc Natl Acad Sci U S A. 2020

Voltin CA, Mettler J, van Heek L, (...) Keller U, (...) Engert A, Kobe C, Bröckelmann PJ: Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial. Clin Cancer Res. 2020

Reinke S, Bröckelmann PJ, Iaccarino I, (...) Mathas S., (...) Keller U, (...) Rosenwald A, Engert A, Klapper W: Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. Blood. 2020

Klinghammer K, Politz O, Eder T, Otto R, (...) Keller U, Keilholz U: Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer. Oncotarget. 2020

Steinebach C, Ng YLD, Sosič I, (...) Luo J, Gütschow M, Krönke J.: Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders. Chem Sci. 2020

Rambaldi A, Iurlo A, Vannucchi AM, (...) Pezzutto A, (...) Bettica P, Manzoni S, Di Tollo S.: Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study. Leukemia. 2020

Rieke DT, Keller U.: A CD205-directed antibody drug conjugate - lymphoma precision oncology or sophisticated chemotherapy? Haematologica. 2020

Röhner L, Ng YLD, Scheffold A, (...), Krönke J.: Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of CrbnI391V. Exp Hematol. 2020

Reimann M, Schrezenmeier JF, Richter-Pechanska P, (...) Busse A, (...) Rosenwald A, Reinhardt HC, Schmitt CA.: Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas. Blood. 2020

Busse A, Mochmann LH, Spenke C, (...) Briest F, (...) Kaemmerer D, Baum RP, Grabowski P.: Immunoprofiling in Neuroendocrine Neoplasms Unveil Immunosuppressive Microenvironment. Cancers (Basel). 2020

Abi Habib J, De Plaen E, Stroobant V, (...) Busse A, Vigneron N, Van den Eynde BJ.: Efficiency of the four proteasome subtypes to degrade ubiquitinated or oxidized proteins. Sci Rep. 2020

Wirth M, Schick M, Keller U, Krönke J.: Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy. Cancers (Basel). 2020

Topp MS, Duell J, Zugmaier G, (...) Krönke J, (...) Minella AC, Munzert G, Einsele H.: Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. J Clin Oncol. 2020 

Hong Y, Singh N, Bamopoulos S, Gjerga E, Schmalbrock LK, Balabanian K, Schick M, Keller U, Wirth M.: Authentication of Primary Murine Cell Lines by a Microfluidics-Based Lab-On-Chip System. Biomedicines. 2020


Scherger, A.K., Al-Maarri, M., Maurer, H.C., (...), Wunderlich, F.T., Rose-John, S., Keller, U.: Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma. JCI Insight. 2019;4.

Hüllein, J., Słabicki, M., Rosolowski, M., (...) Keller, U., Huber, W., Zenz, T.: MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma. Cancer Res. 2019;79:3125-38.

Weber, J., de la Rosa, J., Grove, C.S., (...) Keller, U., Vassiliou, G.S., Cadiñanos, J., Bradley, A., Rad, R.: PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice. Nat Commun. 2019;10:1415.

von Hoff, L., Kärgel, E., Franke, V., (...) Akalin, A., Mathas, S., Scheidereit, C.: Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma. Blood. 2019;133:1489-94.

Edginton-White, B., Cauchy, P., Assi, S.A., (...) Mathas, S., Cockerill, P.N., Bonifer, C.: Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma. Leukemia. 2019;33:1463-74.

Storck, K., Brandstetter, M., Keller, U., Knopf, A.: Clinical presentation and characteristics of lymphoma in the head and neck region. Head Face Med. 2019;15(1):1.

O'Connor, T., Zhou, X., Kosla, J., (...) von Baumgarten, L., Keller, U., Heikenwalder, M.:Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention. Cancer Cell. 2019;36(3):250-267.

Fuchs, M., Goergen, H., Kobe, C., (...) Keller, UB., (...) Dietlein, M., Borchmann, P., Engert, A.: Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. J Clin Oncol. 2019:JCO1900964.

Schroeder, M.P., Bastian, L., Eckert, C., (...) Serve, H., Neumann, M., Baldus, C.D.: Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures. Sci Rep. 2019;9:4188.

Bastian, L., Schroeder, M.P., Eckert, C., (...) Gökbuget, N., Neumann, M., Baldus, C.D.: PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia. Leukemia. 2019.

James, A.R., Schroeder, M.P., Neumann, M., (...) Serve, H., Akalin, A., Baldus, C.D.: Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia. J Hematol Oncol. 2019;12:8.

Maurer, S., Herhaus, P., Lippenmeyer, R., (...) Grigoleit, G.U., Keller, U., Lapa, C.: Side effects of CXC-chemokine receptor 4 - directed Endoradiotherapy with Pentixather prior to Hematopoietic Stem Cell Transplantation. J Nucl Med. 2019.

Nimmagadda, S.C., Frey, S., Müller, P., (...) Keller, U., Edelmann, B., Fischer, T.: SDF1α-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/AKT, PLCγ1 and RhoA. Haematologica. 2019;104:e288-92.

Curran, D., Matthews, S., Rowley, S.D., (...) Schwartz, S., (...) Yeh SP, Zaja F, Szer J; ZOE-HSCT Study group collaborators: Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT). Biol Blood Marrow Transplant. 2019: S1083-8791(19)30508-7

Bastidas, A., de la Serna, J., El Idrissi, M., (...) Schwartz, S., (...) Stadtmauer, E.A., Sullivan, K.M.; ZOE-HSCT Study Group Collaborators: Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. JAMA. 2019;322(2):123-133.

Wagner, K., Kunz, K., Piller, T., (...) Schick, M., Keller, U., Müller, S.: The SUMO Isopeptidase SENP6 Functions as a Rheostat of Chromatin Residency in Genome Maintenance and Chromosome Dynamics. Cell Rep. 2019;29(2):480-494

Lux, M.P., Böhme, S., Hücherig, S., Jeratsch, U., Kürschner, N., Lüftner, D.: Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2019;176:495-506.

Busse, A., Lüftner, D.: What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology? Breast Care (Basel). 2019;14:10-6.
Lüftner, D.: Approval by Authorities Does Not Allow For Suboptimal Study Conduct but Offers New Academic Possibilities. Breast Care (Basel). 2019;14:2-3.

Preisler, M., Rohrmoser, A., Goerling, U., (...) Riemer, M., Heuse, S., Letsch, A.: Early palliative care for those who care: A qualitative exploration of cancer caregivers' information needs during hospital stays. Eur J Cancer Care (Engl). 2019;28:e12990.

Nagel, S.N., Steffen, I.G., Schwartz, S., Hamm, B., Elgeti, T.: Age-dependent diagnostic accuracy of clinical scoring systems and D-dimer levels in the diagnosis of pulmonary embolism with computed tomography pulmonary angiography (CTPA). Eur Radiol. 2019:4563-4571.

Ševa, J., (...) Lamping, M., Rieke, D., (...) Starlinger, J., Keilholz, U., Leser, U.: VIST - a Variant-Information Search Tool for precision oncology. BMC Bioinformatics. 2019;20(1):429.

Schumann, F., Blanc, E., Messerschmidt, C., Blankenstein, T., Busse, A., Beule, D.: SigsPack, a package for cancer mutational signatures. BMC Bioinformatics. 2019;20(1):450.

Çakmak-Görür N, Radke J, Rhein S, (...) Heppner FL, Blankenstein T, Pezzutto A.: Intracellular expression of FLT3 in Purkinje cells: implications for adoptive T-cell therapies. Leukemia. 2019

Horwitz S, O'Connor OA, Pro B, (...) Manley T, Trümper L; ECHELON-2 Study Group.: Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019

Nagel SN, Kim D, Wylutzki T, (...) Schwartz S, Penzkofer T, Hamm B, Elgeti T.:  Diagnostic Performance and Reliability of Non-Enhanced Imaging Characterization Quotients for the Differentiation of Infectious and Malignant Pulmonary Nodules in Hematological Patients Using 3T MRI.  Rofo. 2019

Kotrova M, Volland A, Kehden B, (...) Schwartz S, Baldus CD, Gökbuget N, Brüggemann M.:  Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia. Leukemia. 2019

Klinghammer K, Gauler T, Dietz A, (...) Martus P, Knoedler M, Keilholz U:  Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108).  Eur J Cancer. 2019

Barnell EK, Waalkes A, Mosior MC, (...) Rieke D, (...) Griffith M, Salipante SJ, Griffith OL:  Open-Sourced CIViC Annotation Pipeline to Identify and Annotate Clinically Relevant Variants Using Single-Molecule Molecular Inversion Probes.  JCO Clin Cancer Inform. 2019

Schwartz S, Cornely OA, Hamed K, (...) Rahav G, Herbrecht R, Heinz WJ.: Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.  Med Mycol. 2019

Garralda E, Fiedler W, Matos I, (...) Klinghammer K, (...) Baumeister H, Ochsenreither S, Zurlo A.: Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors.  Ann Oncol. 2019 

Schnürch HG, Ackermann S, Alt-Radtke CD (...) Letsch A (...) Weikel W, Wölber L, Hampl M.: Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1060-1078

Schnürch HG, Ackermann S, Alt-Radtke CD (...) Letsch A (...) Weikel W, Wölber L, Hampl M: Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018). Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1060-1078

Wagner AD, Oertelt-Prigione S, Adjei A (...) Letsch A (...) Moehler M, Peters S, Özdemir BC: Gender medicine and oncology: report and consensus of an ESMO workshop. Ann Oncol. 2019 Dec 1;30(12):1914-1924

Hartkopf AD, Müller V, Wöckel A (...) Lüftner D: Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. Geburtshilfe Frauenheilkd. 2019 Dec;79(12):1309-1319

Lüftner D (...) Untch M, Wuerstlein R, Thill M: Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). Breast Care (Basel). 2019 Oct;14(5):315-324

Welslau M, Hartkopf AD, Müller V (...) Lüftner D (...) Tesch H, Schneeweiss A, Fehm TN: Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1090-1099

Schütz F, Fasching PA, Welslau M (...) Lüftner D, Fehm TN, Schneeweiss A, Müller V: Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1079-1089

Thill M, Jackisch C, Janni W (...) Lüftner D (...) Witzel I, Wöckel A, Ditsch N: AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. Breast Care (Basel). 2019 Aug;14(4):247-255

Ditsch N, Untch M, Thill M (...) Lüftner D (...) Wenz F, Witzel I, Wöckel A: AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care (Basel). 2019 Aug;14(4):224-245

Pivot X, Pegram M, Cortes J, Lüftner D (...) Kim Y, Kim C: Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. Eur J Cancer. 2019 Oct;120:1-9

Untch M, Thomssen C, Bauerfeind I (...) Lüftner D (...) Wuerstlein R, Fasching PA, Harbeck N: Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019). Geburtshilfe Frauenheilkd. 2019 Jun;79(6):591-604

Kolberg HC, Schneeweiss A, Fehm TN (...) Lüftner D (...) Schütz F, Fasching PA, Brucker SY: Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. Geburtshilfe Frauenheilkd. 2019 May;79(5):470-482

Lüftner D: Approval by Authorities Does Not Allow For Suboptimal Study Conduct but Offers New Academic Possibilities. Breast Care (Basel). 2019 Mar;14(1):2-3

Janni W, Schneeweiss A, Müller V (...) Lüftner D (...) Fehm TN, Kolberg HC, Ettl J: Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. Geburtshilfe Frauenheilkd. 2019 Mar;79(3):268-280

Hartkopf AD, Müller V, Wöckel A (...) Lüftner D (...) Overkamp F, Schneeweiss A, Tesch H: Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. Geburtshilfe Frauenheilkd. 2019 Mar;79(3):256-267

Armbrust R, Neeb C, Thuss-Patience P, Lüftner D (...) Richter R, Keller M, Sehouli J: Patients' perspectives towards malignant ascites: results of a prospective observational trial regarding expectations, characteristics and quality of life-a study of the North-Eastern-German Society of Gynecological Oncology. Arch Gynecol Obstet. 2019 May;299(5):1385-1389